© 2018 Miraculo Inc. All Rights Reserved
Who Is Gw?
GW Pharmaceuticals was founded in 1998, with operations in the US and the UK. GW is developing and commercializing plant-derived cannabinoid therapeutics. Their lead product is Epidiolex, which is pure cannabidiol extract for rare, severe, and early-onset, drug-resistant epilepsy. GW developed the world’s first cannabis based prescription medicine, Sativex. Sativex is now approved in numerous countries outside of the United States for the treatment of spasticity due to Multiple Sclerosis (MS).
The company has a pipeline of clinical stage cannabinoid products focused on neurological conditions: Epidiolex for Dravet Syndrome, Lennox Gastaut Syndrome, and Tuberous Sclerosis; CBDV (GWP42006) for Epilepsy and Autism Spectrum Disorders; GWP42003 (IV) for Neonatal Hypoxic-Ischemic Encephalopathy; GWP42002/ GWP42003 for Glioblastoma; and GWP42003 for Schizophrenia.
GW states their primary goal is to “maintain a world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates.” GW’s Chief Executive Officer, Justin Gover, defines the company’s values in their mission statement.
Our primary purpose is to make a positive and meaningful difference in the lives of patients and their caregivers. All of our actions and decisions tie back to this most important and simple fact. Equally, we want our employees to understand and trust that GW Pharmaceuticals and its US subsidiary, Greenwich Biosciences, is committed to doing the right thing. So, we have made it clear what we expect from all of our colleagues.
What Is Sativex?
Sativex (US approved name: nabiximols) is a cannabis sativa plant derived medicine. It particularly contains the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio. THC and CBD are the primary active compounds, but it also includes different minor cannabinoids and non-cannabinoid components.
Sativex is an oromucosal spray. Oromucosal means it is administered across the mucosa of the oral cavity–i.e. the mucous membrane that lines the inside of the mouth. The active ingredients in the spray are absorbed either under the tongue or through the inside of the cheek.
Sativex has received regulatory approval in 30 countries and marketing authorization in 21 of them. GW does not distribute Sativex directly but goes through a range of country-based distributors.
What Is Sativex For?
Sativex was developed to treat MS Spasticity, pain, and chronic cancer pain. The medications primary focus in clinical trials was for the treatment of spasticity (muscle stiffness and spasm) due to MS.
Spasticity is one of the more common symptoms of MS. Spasticity can be as mild as a feeling of tightness of muscles or so severe it produces painful, uncontrollable spasms of extremities, usually of the legs. Spasticity can also cause pain or tightness in and around joints, and lower back pain.
If you’re suffering from MS, seek out medical professionals. Do not take THC or CBD without a prescription to assure legality and proper dosing.